Sugi Holdings (SGIPF) Fair Value & Analysis
Healthcare · US · Market cap $2.9B
Sugi Holdings
SGIPF · US
Fair value as of: Jul 24, 2026
From 24 valuation models · updated 17 days ago
Fair value updated Jul 24, 2026, revised from $29.89 to $29.41 (−1.6%) since Jun 25, 2026. Share price +16.6% over the past month.
A solid business, screening 55% undervalued on our models.
What matters now
- The price is below even our cautious bear case ($22.43). The market is more pessimistic than our downside scenario.
- The model range is unusually wide ($22.43 to $59.45). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- Solid quality (60/100) at a price below fair value, the discount is the argument here, not the business quality.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 24, 2026.
How to read this chart
60‑month range $13.77 – $24.81 · fair‑value band $22.43 – $59.45 · the $18.99 price screens below the $29.41 fair value. Dashed = 300-day average. As of Jul 24, 2026.
Analysis
Sugi Holdings (SGIPF) currently trades at $18.99, while our model-based Fair Value estimate is $29.41, implying the stock looks roughly 54.9% undervalued today. The Quality Score stands at 60/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Sugi Holdings generated revenue of $1.0T at a net margin of 4.5%. Revenue grew 6.9% year over year. It earns a return on equity of 16.6%. The balance sheet holds a net cash position of $17.2B. Fundamentals as of Jul 24, 2026
Our scenario range runs from $22.43 (bear case) to $59.45 (bull case); at $18.99, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 4% below its 52-week high and 20% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at 55%, SGIPF screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Growth Earnings ($69.62) versus Asset-Based ($6.58). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 24, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 64 · Market factors (momentum, volatility) 72
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Sugi Holdings Co.,Ltd. operates drugstores in Japan. The company also provides self-care support services, including meal delivery, cancer and other health checkups, specific health guidance, health information, and community comprehensive agreements; health care support, such as medicine support, home-visit dispensing and nursing, prevention programs, …
Full company description
Sugi Holdings Co.,Ltd. operates drugstores in Japan. The company also provides self-care support services, including meal delivery, cancer and other health checkups, specific health guidance, health information, and community comprehensive agreements; health care support, such as medicine support, home-visit dispensing and nursing, prevention programs, shopping assistance, and mobility support services. In addition, it engages in drugstore operation, dispensing pharmacy operation, medical consultation, business in foreign countries, Chinese medicine pharmacy operations, disease prevention and health support, promotion of disabled employment, home visit nursing and elderly home-care support, support for commencement of medical practice, comprehensive staff agency service, and support business for pharmacy operations. Sugi Holdings Co.,Ltd. was founded in 1976 and is headquartered in Obu, Japan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Sugi Holdings reported revenue of ¥1.0T in FY2026 versus ¥5.4B in FY2022, a compound +269.4%/yr. Reported net income was ¥45.1B in FY2026, compounding +304.4%/yr from FY2022.
Watch SGIPF: get an alert when its fair value changes →
Peer Group
Pharmaceutical Retailers · 61 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Pharmaceutical Retailers median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Jul 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JD Health International Inc 6618 | HK$39.20 | HK$33.28 | -15% |
| Raia Drogasil S.A RADL3 | R$18.20 | R$15.58 | -14% |
| Yifeng Pharmacy Chain Co 603939 | ¥20.24 | ¥29.07 | +44% |
| DaShenLin Pharmaceutical Group 603233 | ¥17.81 | ¥23.86 | +34% |
| Corporativo Fragua, S.A. FRAGUAB | 463.00 MXN | 821.18 MXN | +77% |
| LBX Pharmacy Chain Joint Stock Company 603883 | ¥11.51 | ¥10.57 | -8% |
| MedPlus Health Services Limited MEDPLUS | ₹690.20 | ₹379.25 | -45% |
| Yixintang Pharmaceutical Group 002727 | ¥11.46 | ¥9.45 | -18% |
| Anhui Huaren Health Pharmaceutical Co 301408 | ¥14.40 | ¥10.05 | -30% |
| Apotea AB APOTEA | kr 74.75 | kr 43.95 | -41% |
Compare Sugi Holdings with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Sugi Holdings (SGIPF) overvalued or undervalued?
What is the fair value of SGIPF?
What is the quality score of SGIPF?
What is the revenue of Sugi Holdings (SGIPF)?
What is the net profit margin of SGIPF?
Does Sugi Holdings pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Sugi Holdings and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.